-

Aqemia Announces Pilot Study with Janssen to Utilize Aqemia’s Physics-driven Drug Discovery Technology

ANTWERP, Belgium and PARIS--(BUSINESS WIRE)--Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen.

Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets.

The agreement aims at building a common understanding of the performance of Aqemia’s technology and how best to apply it in drug discovery projects on different types of target proteins and diseases. It includes an upfront payment from Janssen.

Maximilien Levesque, CEO and co-founder of Aqemia, commented, “We are very happy to start working with Janssen’s teams to apply our unique technology to drug discovery projects”. He added, “This is a great opportunity for us to demonstrate the scalability and repeatability of Aqemia’s recent successes in drug discovery projects.”

About Aqemia

Aqemia is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates. The disruptive speed and accuracy of our technological platform enables us to scale drug discovery projects just like tech projects.

For more information visit us on www.aqemia.com or follow us on LinkedIn.

Contacts

Aqemia contacts:
Maximilien Levesque: maximilien.levesque@aqemia.com
Emmanuelle Martiano: emmanuelle.martiano@aqemia.com

Industry:

Aqemia

Release Versions
English

Contacts

Aqemia contacts:
Maximilien Levesque: maximilien.levesque@aqemia.com
Emmanuelle Martiano: emmanuelle.martiano@aqemia.com

Social Media Profiles
Aqemia/LinkedIn
More News From Aqemia

Aqemia Advances Epitranscriptomics Programs and Expands into Small-Molecule RNA Targeting with $7.4 Million Grant

PARIS & LONDON--(BUSINESS WIRE)--Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. In parallel with advancing RNA-focused initiatives, the company continues to drive innovation in its broader pipeline, including protein-targeting programs. New Fun...

AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK

PARIS & LONDON--(BUSINESS WIRE)--AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows...

AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier

PARIS--(BUSINESS WIRE)--AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology. Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully...
Back to Newsroom